escitalopram and sertraline

ApprovedSmall molecule

escitalopram and sertraline is one of 4 small molecule programs targeting Dysthymic Disorder. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Dysthymic DisorderActive, not recruiting

Dysthymic DisorderApproved

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Dysthymic Disorder

#DrugCompanyPhaseTrials

Bupropion XL

GSK

Approved

1 2

Lexapro

SShirley Ryan AbilityLab

Approved

1 3

escitalopram and sertraline

OOregon Health and Science University

Approved

1 4

Pristiq

PPrism Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dysthymic Disorder1 trial

Medications for the Treatment of Dysthymic Disorder and Double Depression

Completed·OOregon Health and Science University·Phase 4·NCT00234312·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for escitalopram and sertraline. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — escitalopram and sertraline compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for escitalopram and sertraline. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Oregon Health and Science University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: OOregon Health and Science University

escitalopram and sertraline

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Dysthymic Disorder1 trial

References

Drug Info

Quick Facts

Related News